Modulation of interleukin‐6 (IL‐6) signaling affects the production of autoantibodies and suppresses disease activity in neuromyelitis optica [72], and a phase 3 trial with satralizumab in generalized MG is ongoing (NCT04963270). Here, IL6 is linked to myasthenia gravis.